A study in healthy neonates of safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured using a modified process
Latest Information Update: 21 Jul 2022
Price :
$35 *
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 05 Jan 2012 Results published in Vaccine.
- 24 Feb 2009 Actual end date (Aug 2007) added as reported by ClinicalTrials.gov.
- 18 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.